



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/85021/2023

European Medicines Agency decision P/0072/2023

of 10 March 2023

on the agreement of a paediatric investigation plan and on the granting of a waiver for humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220) (EMEA-003215-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0072/2023

of 10 March 2023

on the agreement of a paediatric investigation plan and on the granting of a waiver for humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220) (EMEA-003215-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Roche Registration GmbH on 18 March 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 January 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220), solution for injection, intravitreal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220), solution for injection, intravitreal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 - Grenzach-Wyhlen, Germany.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/869388/2022
Amsterdam, 20 January 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA-003215-PIP01-22

Scope of the application

Active substance(s):

Humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of uveitic macular oedema

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intravitreal use

Name/corporate name of the PIP applicant:

Roche Registration GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Roche Registration GmbH submitted for agreement to the European Medicines Agency on 18 March 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 25 April 2022.

Supplementary information was provided by the applicant on 17 October 2022. The applicant proposed modifications to the paediatric investigation plan and waiver and withdrew its request for a deferral.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of uveitic macular oedema

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, intravitreal use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of uveitic macular oedema

2.1.1. Indication(s) targeted by the PIP

Treatment of uveitic macular oedema

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Double-blind, randomised trial to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of RO7200220 compared to sham control in children from 2 years to less than 18 years of age (and adults) with uveitic macular oedema (UME) Study 2 Double-blind, randomised trial to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of RO7200220 compared to sham control in children from 2 years to less than 18 years of age (and adults) with uveitic macular oedema (UME)

Modelling and simulation studies	Study 3 Population pharmacokinetic (PopPK) analysis of RO7200220
Other studies	Not applicable
Extrapolation plan	Studies 1, 2 and 3 are part of an extrapolation plan covering the paediatric population from 2 years to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2025
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.